Beam Therapeutics

company

About

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$260M
Industries
Biotechnology,Genetics,Medical,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:BEAM
Legal Name
Beam Therapeutics, Inc.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$867M
Beam Therapeutics has raised a total of $867M in funding over 2 rounds. Their latest funding was raised on Jan 19, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 19, 2021 Post-IPO Equity $260M 5 Detail
Feb 11, 2020 Post-IPO Equity $207M Detail
Feb 5, 2020 IPO $178M Detail
Mar 6, 2019 Series B $135M 8 Detail
May 14, 2018 Series A $87M 3 ARCH Venture Partners
F-Prime Capital
Detail

Employee Profiles

Number of Employee Profiles
25
Beam Therapeutics has 25 current employee profiles, including Executive Adam Fung
Executive
Executive
Executive
Executive
Executive

Acquisition

Beam Therapeutics has acquired 1 organizations. Their most recent acquisition was Guide Therapeutics on Feb 23, 2021. They acquired Guide Therapeutics for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition Detail